UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 124

Sortiert nach

Prognostic Factors for the Outcome of Chemotherapy in Advanced Soft Tissue Sarcoma: An Analysis of 2,185 Patients Treated With Anthracycline-Containing First-Line Regimens—A European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study

Journal of clinical oncology, 1999-01, Vol.17 (1), p.150-157

1999

Volltextzugriff (PDF)

Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group

European journal of cancer (1990), 2002-03, Vol.38 (4), p.556-559

2002

Volltextzugriff (PDF)

Vascular endothelial growth factor measured in platelet poor plasma allows optimal separation between cancer patients and volunteers: A key to study an angiogenic marker in vivo?

Annals of oncology, 1999-08, Vol.10 (8), p.965-971

1999

Volltextzugriff (PDF)

Phase I and Pharmacokinetic Study of Oral Irinotecan Given Once Daily for 5 Days Every 3 Weeks in Combination With Capecitabine in Patients With Solid Tumors

Journal of clinical oncology, 2005-02, Vol.23 (4), p.889-898

2005

Volltextzugriff (PDF)

Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours

European journal of cancer (1990), 2006, Vol.42 (1), p.50-54

2006

Volltextzugriff (PDF)

Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours

European journal of cancer (1990), 2003-05, Vol.39 (7), p.917-926

2003

Volltextzugriff (PDF)

Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL®/CAELYX®) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group

European journal of cancer (1990), 2001-05, Vol.37 (7), p.870-877

2001

Volltextzugriff (PDF)

9425 Administration of 24-hour intravenous infusions of trabectedin (Yondelis®) every 3 weeks in ambulatory patients with mesenchymal tumors via the disposable elastomeric pump Baxter LV10: a feasible, convenient, effective and patient-friendly palliative treatment option

European journal of cancer supplements, 2009, Vol.7 (2), p.597-597

2009

Volltextzugriff (PDF)

Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients

European journal of cancer (1990), 2002-12, Vol.38 (18), p.2397-2406

2002

Volltextzugriff (PDF)

Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy

European journal of cancer (1990), 2003, Vol.39 (1), p.64-69

2003

Volltextzugriff (PDF)

The present state of the art in chemotherapy for soft tissue sarcomas in adults: the EORTC point of view

Critical reviews in oncology/hematology, 1995-10, Vol.20 (3), p.193-201

1995

Volltextzugriff (PDF)

Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors

Annals of oncology, 2004-05, Vol.15 (5), p.831-838

2004

Volltextzugriff (PDF)

A real-time quantitative reverse transcriptase polymerase chain reaction (RT-PCR) to detect breast carcinoma cells in peripheral blood

Annals of oncology, 2001-01, Vol.12 (1), p.39-46

2001

Volltextzugriff (PDF)

Isolated lung perfusion with melphalan and tumor necrosis factor for metastatic pulmonary adenocarcinoma

The Annals of thoracic surgery, 1998-11, Vol.66 (5), p.1719-1724

1998

Volltextzugriff (PDF)

40 years of the EORTC

European journal of cancer (1990), 2002-03, Vol.38, p.3-13

2002

Volltextzugriff (PDF)

PII: S0959-8049(01)00457-9

European journal of cancer (1990), 2002, Vol.38, p.1-2

2002

Volltextzugriff (PDF)

Serum basic fibroblast growth factor and vascular endothelial growth factor and tumour growth kinetics in advanced colorectal cancer

Annals of oncology, 1996-10, Vol.7 (8), p.843-848

1996

Volltextzugriff (PDF)

Sensitive and specific quantification of the anticancer agent ZD1839 (Gefitinib) in plasma by on-column focusing capillary liquid chromatography–tandem mass spectrometry

Journal of Chromatography A, 2005-07, Vol.1082 (1), p.2-5

2005

Volltextzugriff (PDF)

Combretastatin A-4 phosphate enhances CPT-11 activity independently of the administration sequence

European journal of cancer (1990), 2004-01, Vol.40 (2), p.284-290

2004

Volltextzugriff (PDF)

Nanotechnology in bio/clinical analysis

Journal of chromatography. B, Biomedical sciences and applications, 2000-02, Vol.739 (1), p.139-150

2000

Volltextzugriff (PDF)

Quantitative pathologic features as predictors of long‐term survival in patients with advanced ovarian cancer treated with cisplatin

International journal of gynecological cancer, 1994-05, Vol.4 (3), p.174-179

1994

Volltextzugriff (PDF)

Docetaxel (Taxotere®): An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck

Annals of oncology, 1994-07, Vol.5 (6), p.533-537

1994

Volltextzugriff (PDF)

Phase II study with Docetaxel (Taxotere®) in advanced soft tissue sarcomas of the adult

Annals of oncology, 1994-07, Vol.5 (6), p.539-542

1994

Volltextzugriff (PDF)

Hyphenated techniques in anticancer drug monitoring: I. Capillary gas chromatography–mass spectrometry

Journal of Chromatography A, 2002-11, Vol.976 (1), p.229-238

2002

Volltextzugriff (PDF)

Long-term survival in ovarian cancer: Mature data from The Netherlands joint study group for ovarian cancer

European journal of cancer & clinical oncology, 1991, Vol.27 (11), p.1367-1372

1991

Volltextzugriff (PDF)

1 – 25 von 124

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(106)
Mit Volltextzugriff
(114)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(68)
Humans
(66)
Life Sciences & Biomedicine
(64)
Biological And Medical Sciences
(57)
Medical Sciences
(55)
Female
(48)
Oncology
(46)
Pharmacology. Drug Treatments
(40)
Middle Aged
(35)
Adult
(34)
Male
(33)
Chemotherapy
(32)
Aged
(31)
Antineoplastic Agents
(31)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(24)
Tumors
(16)
Cisplatin - Administration & Dosage
(12)
Sarcoma - Drug Therapy
(11)
Antineoplastic Agents - Therapeutic Use
(10)
Prognosis
(10)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Prognostic Factors for the Outcome of Chemotherapy in Advanced Soft Tissue Sarcoma: An Analysis of 2,185 Patients Treated With Anthracycline-Containing First-Line Regimens—A European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study

Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group

Vascular endothelial growth factor measured in platelet poor plasma allows optimal separation between cancer patients and volunteers: A key to study an angiogenic marker in vivo?

Phase I and Pharmacokinetic Study of Oral Irinotecan Given Once Daily for 5 Days Every 3 Weeks in Combination With Capecitabine in Patients With Solid Tumors

Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours

Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours

Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL®/CAELYX®) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group

9425 Administration of 24-hour intravenous infusions of trabectedin (Yondelis®) every 3 weeks in ambulatory patients with mesenchymal tumors via the disposable elastomeric pump Baxter LV10: a feasible, convenient, effective and patient-friendly palliative treatment option

Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients

Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy

The present state of the art in chemotherapy for soft tissue sarcomas in adults: the EORTC point of view

Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors

A real-time quantitative reverse transcriptase polymerase chain reaction (RT-PCR) to detect breast carcinoma cells in peripheral blood

Isolated lung perfusion with melphalan and tumor necrosis factor for metastatic pulmonary adenocarcinoma

40 years of the EORTC

PII: S0959-8049(01)00457-9

Serum basic fibroblast growth factor and vascular endothelial growth factor and tumour growth kinetics in advanced colorectal cancer

Sensitive and specific quantification of the anticancer agent ZD1839 (Gefitinib) in plasma by on-column focusing capillary liquid chromatography–tandem mass spectrometry

Combretastatin A-4 phosphate enhances CPT-11 activity independently of the administration sequence

Nanotechnology in bio/clinical analysis

Quantitative pathologic features as predictors of long‐term survival in patients with advanced ovarian cancer treated with cisplatin

Docetaxel (Taxotere®): An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck

Phase II study with Docetaxel (Taxotere®) in advanced soft tissue sarcomas of the adult

Hyphenated techniques in anticancer drug monitoring: I. Capillary gas chromatography–mass spectrometry

Long-term survival in ovarian cancer: Mature data from The Netherlands joint study group for ovarian cancer

Suchergebnisse filtern